Carle Provider - Suparna Mantha, MD

Dr. Suparna Mantha

Claim this profile

Carle Cancer Center

Studies Colorectal Cancer
Studies Colon Cancer
35 reported clinical trials
78 drugs studied

Area of expertise

1

Colorectal Cancer

Suparna Mantha has run 5 trials for Colorectal Cancer. Some of their research focus areas include:

Stage IV
Stage III
dMMR negative
2

Colon Cancer

Suparna Mantha has run 5 trials for Colon Cancer. Some of their research focus areas include:

Stage IV
Stage III
BRAF negative

Affiliated Hospitals

Image of trial facility.

Carle Physician Group-Mattoon/Charleston

Image of trial facility.

Carle Cancer Center

Clinical Trials Suparna Mantha is currently running

Image of trial facility.

Atezolizumab + Multi-Kinase Inhibitor

for Liver Cancer

This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.

Recruiting

1 award

Phase 2

3 criteria

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Recruiting

1 award

Phase 2

7 criteria

More about Suparna Mantha

Clinical Trial Related

6 years of experience running clinical trials · Led 35 trials as a Principal Investigator · 16 Active Clinical Trials

Treatments Suparna Mantha has experience with

  • Atezolizumab
  • Fluorouracil
  • Venetoclax
  • Bevacizumab
  • Nivolumab
  • Biospecimen Collection

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Suparna Mantha specialize in?

Is Suparna Mantha currently recruiting for clinical trials?

Are there any treatments that Suparna Mantha has studied deeply?

What is the best way to schedule an appointment with Suparna Mantha?

What is the office address of Suparna Mantha?

Is there any support for travel costs?